SNOA - オクルス・イノベイティブ・サイエンス (Sonoma Pharmaceuticals Inc.)

SNOAのニュース

   ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA  2020/12/24 21:07:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma’s “unaudited condensed consolidate
   Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today  2020/12/18 17:13:40 Benzinga
Sonoma Pharmaceuticals (NASDAQ: SNOA ) shares are … Full story available on Benzinga.com
   Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets  2020/12/17 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Gabriel Science enter into distribution agreement for the sale of HOCl-products into the dental markets.
   SNOA Stock: Sonoma Pharmaceuticals Heads up on Partnership News  2020/12/11 14:16:02 CNA Finance
SNOA stock is headed for the top in the market after announcing it has entered into a new partnership with Crown Laboratories.
   Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products  2020/12/10 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Crown Laboratories announce an exclusive partnership to launch Microcyn® Technology-based anti-itch OTC products.
   ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA  2020/12/24 21:07:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma’s “unaudited condensed consolidate
   Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today  2020/12/18 17:13:40 Benzinga
Sonoma Pharmaceuticals (NASDAQ: SNOA ) shares are … Full story available on Benzinga.com
   Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets  2020/12/17 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Gabriel Science enter into distribution agreement for the sale of HOCl-products into the dental markets.
   SNOA Stock: Sonoma Pharmaceuticals Heads up on Partnership News  2020/12/11 14:16:02 CNA Finance
SNOA stock is headed for the top in the market after announcing it has entered into a new partnership with Crown Laboratories.
   Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products  2020/12/10 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Crown Laboratories announce an exclusive partnership to launch Microcyn® Technology-based anti-itch OTC products.
   Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2020 Financial Results  2020/07/10 21:00:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions today announced financial results for fiscal year 2020 and the fourth quarter ended March 31, 2020. “We began this fiscal year with a goal of reducing our losses and cash burn and are pleased with an 75% drop in our net loss whil
   Sonoma Pharmaceuticals : Annual report pursuant to Section 13 and 15(d) | MarketScreener  2020/07/10 20:16:04 MarketScreener
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form… | July 10, 2020
   Sonoma Pharmaceuticals stock nearly triples after disinfectant allowed to carry COVID-19 label in Australia  2020/05/29 12:20:38 MarketWatch
Shares of Sonoma Pharmaceuticals Inc. undefined nearly tripled on heavy volume in premarket trading Friday, after the California-based producer of…
   Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered Into the Australian Register of Therapeutic Goods (ARTG) for use against COVID-19  2020/05/28 20:30:00 Business Wire
PETALUMA, Calif.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, and its partner, the MicroSafe Group, Dubai, announce an important break-through in the fight of the global coronavirus pandemic. MicroSafe Care Australia received approval for their patented and trademarked Nanocyn® Disinfect
   Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe and approval of new CE Marking for Microdacyn60® Eye Care  2020/05/26 20:57:00 Business Wire
PETALUMA, Calif.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, is pleased to announce that it received a new CE Marking (Conformité Européenne) for its Microdacyn60® Eye Care based on Sonoma’s patented Microcyn® Technology. The formulation, marketed in the United States as Acuicyn™ Antimi

calendar